Study of Vorinostat Plus Melphalan and Prednisone (Zmp) in Advanced, Refractory Multiple Myeloma Patients
The purpose of this study is to determine whether the association of ZMP is safe and provides benefits in patients with relapsed/refractory MM.
Multiple Myeloma
DRUG: Vorinostat
The dose limiting toxicity (DLT)of Vorinostat with MP, one year|The maximum tolerated dose (MTD) of Vorinostat in association with MP, 1 year|A significant number of PR or higher (>40%) following the proposed ZMP therapy, 1 year
Duration of Progression Free Survival, 5 Years|Duration of Overall Survival, 5 years
The purpose of this study is to determine whether the association of ZMP is safe and provides benefits in patients with relapsed/refractory MM.